Hallek, Michael, Prof. Dr. med.

Status: Professor and Chairman
Address: Clinic I of Internal Medicine
University Hospital Cologne 
Kerpenerstr. 62
50937 Cologne
Phone: +49 221/478 4400
E-Mail: michael.hallek@uni-koeln.de
Nationality: German


Education

1985 Final medical examination, Technical University of Munich
1986 MD thesis, University of Munich
1995 Habilitation (PhD thesis), University Munich
1996 Board examination internal medicine
1998 Board examination hematology and oncology


Professional and research experience

1985-1987 Scientific assistant, Inst Pharmacol. Toxicol. Univ. Munich & German Army
1987-1990

Ass. Physician, Internal Medicine TU and Univ. Munich (Prof.s Bloemer, Buchborn)

1990-1992 Research Associate, Dana Farber Cancer Inst. & Harvard Med. School (Prof. Griffin)
1992-1995 Ass. Physician, Med. Klinik Innenstadt, Univ. Munich (Prof. Scriba)
1994-2005 Research Group Leader, Gene Center Univ. Munich (Prof. Winnacker)
1995-2003 Senior consultant, Univ. Munich (Prof. Scriba, Prof. Hiddemann)
1998-2005

Head, Clinical Cooperation Group for Gene Therapy, National Centre for Research on Environment and Health (GSF), Munich

1999-2003 Professor (C3) of Medicine, University of Munich
2003 Professor (C4), Director and Chair, Dept. Internal Medicine I, Univ. Cologne
2007 Director, Center for Integrated Oncology, Univ. Cologne and Bonn.


Awards and honours (selected)

1978-1985 Stipends  Bayerisches Begabtenförderungsgesetz and the Cusanuswerk
1982-1983 Grant of German Academic Exchange Service and French Government
1990-1992 Research fellowship of German Research Council (DFG)
1999 Artur-Pappenheim-Price, German Society of Hematology and Oncology
2000

Scientific Advisory Board (Core Group) of the International Working Group on CLL (IWCLL)

2007 and 2011

Center for Integrated Oncology Köln-Bonn awarded Center of Excellence in Oncology

2011 Member of the National Academy of Science (Leopoldina)
2012 Paul Martini Prize
2013 Binet-Rai-Medal of the International Workshop on CLL (iwCLL)


List of the five most important publications

1.   Landau, D.A., Tausch, E., Taylor-Weiner, A.N., Stewart, C., Reiter, J.G., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Bottcher, S., Carter, S.L., Cibulskis, K., Mertens, D., Sougnez, C.L., Rosenberg, M., Hess, J.M., Edelmann, J., Kless, S., Kneba, M., Ritgen, M., Fink, A., Fischer, K., Gabriel, S., Lander, E.S., Nowak, M.A., Dohner, H., Hallek, M.*, Neuberg, D.*, Getz, G.*, Stilgenbauer, S.*, and Wu, C.J*. (2015). Mutations driving CLL and their evolution in progression and relapse. Nature 526, 525-530.

2.   Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C.M., Chagorova, T., de la Serna, J., Dilhuydy, M.S., Illmer, T., Opat, S., Owen, C.J., Samoylova, O., Kreuzer, K.A., Stilgenbauer, S., Dohner, H., Langerak, A.W., Ritgen, M., Kneba, M., Asikanius, E., Humphrey, K., Wenger, M., and Hallek, M. (2014). Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370, 1101-1110.

3.   Furman, R.R., Sharman, J.P., Coutre, S.E., Cheson, B.D., Pagel, J.M., Hillmen, P., Barrientos, J.C., Zelenetz, A.D., Kipps, T.J., Flinn, I., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A.R., Ma, S., Stilgenbauer, S., Cramer, P., Aiello, M., Johnson, D.M., Miller, L.L., Li, D., Jahn, T.M., Dansey, R.D., Hallek, M., and O'Brien, S.M. (2014). Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370, 997-1007.

4.   Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H., Stilgenbauer, S., International Group of, I., and German Chronic Lymphocytic Leukaemia Study, G. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164-1174.

5.   Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deleage, G., and Hallek, M. (1999). Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 5, 1438.